Enduring Material

• Design initial acne treatment regimens that minimize irritation and improve adherence.
• Select appropriate topical treatments for pediatric atopic dermatitis, including steroid potency, vehicle, and indications for non-steroidal agents.

• Connecticut Children's Office of Continuing Medical Education designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
• The Connecticut Children's designates this enduring material for a maximum of 0.5 Hour(s) Attendance w/ No Credit. Participants should claim only the credit commensurate with the extent of their participation in the activity.

Keri Wallace, MD has no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients to disclose.

Keri Wallace, MD has indicated the presentation may include discussion of any off-label uses of a product. Explanation Given: I may (possibly) discuss the off label use of topical calcineurin inhibitors in children <2 as there is currently only 1 FDA-approved non-steroidal topical agent approved for the treatment of eczema in this age group.

Connecticut Children's is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Connecticut Children's awards this live activity for a maximum of .5 AMA PRA Category 1 Credit™. Conflict of Interest Policy: All faculty participating in Continuing Medical Education activities sponsored by Connecticut Children’s are required to disclose to the program audience any actual or perceived conflict of interest related to the content of their presentation. Program planners have an obligation to resolve any actual conflicts of interest and share with the audience any safeguards put in place to prevent commercial bias from influencing the content. The planners, activity director and speaker(s) do not have a financial interest/arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation. Keri Wallace, MD has indicated the presentation may include discussion of any off-label uses of a products, ie. use of topical calcineurin inhibitors in children <2 as there is currently only 1 FDA-approved non-steroidal topical agent approved for the treatment of eczema in this age group.

This activity is not commercially supported.

• Connecticut Children's is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. Connecticut Children's takes responsibility for the content, quality, and scientific integrity of this CME activity.

75 %

100 %

10/1/2025